Neurocrine Biosciences, Inc. (NBIX) Insider Sells $31,355.51 in Stock, Report finds

Neurocrine Biosciences, Inc. (NBIX) Insider Sells $31,355.51 in Stock, Report finds

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Dimitri E. Grigoriadis sold 727 shares of Neurocrine Biosciences stock in a transaction that occurred on Monday, February 6th. The shares were sold at an average price of $43.13, for a total value of $31,355.51. Following the sale, the insider now owns 115,756 shares in the company, valued at $4,992,556.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) traded up 0.57% during mid-day trading on Wednesday, reaching $43.85. The company had a trading volume of 745,356 shares. The stock’s 50-day moving average price is $41.06 and its 200 day moving average price is $46.44. Neurocrine Biosciences, Inc. has a 52 week low of $31.55 and a 52 week high of $55.15. The firm’s market capitalization is $3.81 billion.

Several research firms recently weighed in on NBIX. Robert W. Baird restated a “buy” rating and set a $66.00 price target on shares of Neurocrine Biosciences in a research report on Sunday, January 8th. Needham & Company LLC reissued a “buy” rating and issued a $62.00 target price on shares of Neurocrine Biosciences in a report on Wednesday, January 18th. Oppenheimer Holdings, Inc. raised Neurocrine Biosciences from a “market perform” rating to an “outperform” rating and set a $55.00 target price on the stock in a report on Friday, January 27th. They noted that the move was a valuation call. Piper Jaffray Companies reissued an “overweight” rating and issued a $96.00 target price on shares of Neurocrine Biosciences in a report on Thursday, November 3rd. Finally, Barclays PLC reissued a “buy” rating and issued a $60.00 target price on shares of Neurocrine Biosciences in a report on Thursday, November 3rd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and thirteen have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $66.31.

A number of hedge funds have recently made changes to their positions in the stock. ClariVest Asset Management LLC boosted its stake in shares of Neurocrine Biosciences by 15.4% in the second quarter. ClariVest Asset Management LLC now owns 39,701 shares of the company’s stock valued at $1,804,000 after buying an additional 5,300 shares during the period. Quantitative Systematic Strategies LLC bought a new stake in shares of Neurocrine Biosciences during the second quarter valued at about $321,000. Tocqueville Asset Management L.P. boosted its stake in shares of Neurocrine Biosciences by 4.4% in the second quarter. Tocqueville Asset Management L.P. now owns 42,900 shares of the company’s stock valued at $1,950,000 after buying an additional 1,800 shares during the period. Artal Group S.A. bought a new stake in shares of Neurocrine Biosciences during the second quarter valued at about $4,318,000. Finally, Laurion Capital Management LP bought a new stake in shares of Neurocrine Biosciences during the second quarter valued at about $7,876,000. 97.73% of the stock is currently owned by institutional investors and hedge funds.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is engaged in the development of pharmaceutical products focused on neurological and endocrine-based diseases and disorders. The Company’s two lead late-stage clinical programs are Elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for women’s health that is partnered with AbbVie Inc (AbbVie), and NBI-98854 (valbenazine), a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders.

Related posts

Leave a Comment

Neurocrine Biosciences, Inc. (NBIX) Insider Sells $31,355.51 in Stock

Neurocrine Biosciences, Inc. (NBIX) Insider Sells $31,355.51 in Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Dimitri E. Grigoriadis sold 727 shares of Neurocrine Biosciences stock in a transaction that occurred on Monday, February 6th. The shares were sold at an average price of $43.13, for a total value of $31,355.51. Following the sale, the insider now owns 115,756 shares in the company, valued at $4,992,556.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) traded up 0.57% during mid-day trading on Wednesday, reaching $43.85. The company had a trading volume of 745,356 shares. The stock’s 50-day moving average price is $41.06 and its 200 day moving average price is $46.44. Neurocrine Biosciences, Inc. has a 52 week low of $31.55 and a 52 week high of $55.15. The firm’s market capitalization is $3.81 billion.

Several research firms recently weighed in on NBIX. Robert W. Baird restated a “buy” rating and set a $66.00 price target on shares of Neurocrine Biosciences in a research report on Sunday, January 8th. Needham & Company LLC reissued a “buy” rating and issued a $62.00 target price on shares of Neurocrine Biosciences in a report on Wednesday, January 18th. Oppenheimer Holdings, Inc. raised Neurocrine Biosciences from a “market perform” rating to an “outperform” rating and set a $55.00 target price on the stock in a report on Friday, January 27th. They noted that the move was a valuation call. Piper Jaffray Companies reissued an “overweight” rating and issued a $96.00 target price on shares of Neurocrine Biosciences in a report on Thursday, November 3rd. Finally, Barclays PLC reissued a “buy” rating and issued a $60.00 target price on shares of Neurocrine Biosciences in a report on Thursday, November 3rd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and thirteen have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $66.31.

A number of hedge funds have recently made changes to their positions in the stock. ClariVest Asset Management LLC boosted its stake in shares of Neurocrine Biosciences by 15.4% in the second quarter. ClariVest Asset Management LLC now owns 39,701 shares of the company’s stock valued at $1,804,000 after buying an additional 5,300 shares during the period. Quantitative Systematic Strategies LLC bought a new stake in shares of Neurocrine Biosciences during the second quarter valued at about $321,000. Tocqueville Asset Management L.P. boosted its stake in shares of Neurocrine Biosciences by 4.4% in the second quarter. Tocqueville Asset Management L.P. now owns 42,900 shares of the company’s stock valued at $1,950,000 after buying an additional 1,800 shares during the period. Artal Group S.A. bought a new stake in shares of Neurocrine Biosciences during the second quarter valued at about $4,318,000. Finally, Laurion Capital Management LP bought a new stake in shares of Neurocrine Biosciences during the second quarter valued at about $7,876,000. 97.73% of the stock is currently owned by institutional investors and hedge funds.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is engaged in the development of pharmaceutical products focused on neurological and endocrine-based diseases and disorders. The Company’s two lead late-stage clinical programs are Elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for women’s health that is partnered with AbbVie Inc (AbbVie), and NBI-98854 (valbenazine), a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders.

Related posts

Leave a Comment